Ubs Group Ag Immuneering Corp Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
A detailed history of Ubs Group Ag transactions in Immuneering Corp stock. As of the latest transaction made, Ubs Group Ag holds 52,493 shares of IMRX stock, worth $65,091. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52,493
Previous 31,545
66.41%
Holding current value
$65,091
Previous $78,000
47.44%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding IMRX
# of Institutions
42Shares Held
4.52MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.06MShares$1.31 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD767KShares$951,2330.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$661,3710.0% of portfolio
-
Morgan Stanley New York, NY454KShares$563,0840.0% of portfolio
-
Southport Management, L.L.C. Wilson, WY215KShares$266,6001.71% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $32.7M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...